Xenon Pharmaceuticals (XENE) Set to Post Quarterly Earnings on Monday

Key Points

• Xenon Pharmaceuticals is scheduled to report Q3 2026 results after the market closes on November 2. Analysts expect a loss of $1.13 per share on $1.33 million in revenue; the company reported a $1.11-per-share loss in the previous quarter, ahead of estimates.
• XENE opened at $35.34, near its 12-month low of $33.38 and well below its 12-month high of $72.66. The stock’s market capitalization is approximately $3.42 billion.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $70.14, although several firms recently reduced their targets. CEO Ian Mortimer also purchased 30,000 shares, while another insider sold shares to cover tax withholding obligations.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) is expected to issue its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to post earnings of ($1.13) per share and revenue of $1.33 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.05. During the same quarter in the prior year, the firm posted ($1.07) EPS. On average, analysts expect Xenon Pharmaceuticals to post ($4.66) EPS for the current fiscal year and ($4.83) EPS for the next fiscal year.

Xenon Pharmaceuticals Stock Performance

NASDAQ:XENE opened at $35.34 on Monday. The company has a market cap of $3.42 billion, a price-to-earnings ratio of -7.46 and a beta of 0.60. Xenon Pharmaceuticals has a twelve month low of $33.38 and a twelve month high of $72.66. The stock has a fifty day simple moving average of $47.83 and a 200-day simple moving average of $54.93.

Insider Activity

In other news, CEO Ian Mortimer bought 30,000 shares of the stock in a transaction on Wednesday, September 30th. The stock was bought at an average cost of $37.38 per share, for a total transaction of $1,121,400.00. Following the completion of the purchase, the chief executive officer directly owned 49,923 shares in the company, valued at approximately $1,866,121.74. The trade was a 150.58% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Kenney sold 7,068 shares of Xenon Pharmaceuticals stock in a transaction on Friday, August 28th. The stock was sold at an average price of $60.25, for a total transaction of $425,847.00. Following the completion of the transaction, the insider directly owned 2 shares in the company, valued at $120.50. This represents a 99.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.91% of the company's stock.

Analysts Set New Price Targets

XENE has been the topic of several research analyst reports. Royal Bank Of Canada dropped their price objective on Xenon Pharmaceuticals from $81.00 to $70.00 and set an "outperform" rating on the stock in a research note on Friday, September 18th. HC Wainwright reaffirmed a "buy" rating on shares of Xenon Pharmaceuticals in a research report on Friday, September 18th. Needham & Company LLC dropped their price target on Xenon Pharmaceuticals from $78.00 to $60.00 and set a "buy" rating on the stock in a research report on Friday, September 18th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, September 28th. Finally, Wells Fargo & Company dropped their target price on shares of Xenon Pharmaceuticals from $69.00 to $64.00 and set an "overweight" rating on the stock in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $70.14.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for neurological and psychiatric disorders. The company uses expertise in human genetics and ion-channel biology to identify potential treatments for diseases with significant unmet medical needs, particularly epilepsy and other disorders of the nervous system.

Xenon's lead investigational product is azetukalner, also known as XEN1101, a selective potassium-channel opener being evaluated for epilepsy and other potential neurological and psychiatric applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.